Satellite Allows Digital Mammography Screening for Rural Native Americans

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 3
Volume 16
Issue 3

A mobile mammography unit that links a digital mammography system with a commercial satellite service provides near real-time interpretation of breast imaging scans to Native American women on remote rural reservations

CHICAGO—A mobile mammography unit that links a digital mammography system with a commercial satellite service provides near real-time interpretation of breast imaging scans to Native American women on remote rural reservations, Marilyn Roubidoux, MD, professor of radiology, University of Michigan Health System, said at the 92nd Annual Meeting of the Radiological Society of North America (RSNA) (abstract SSJ01-04) (see Figures 1 and 2).

In the study, digital mammograms were transmitted by satellite from the Aberdeen Area Indian Health Service, Fort Yates, North Dakota, to the University of Michigan Breast Imaging Division in Ann Arbor. Although the size of the mammography image files was extremely large, transmission time averaged only about 5 minutes per file. The mean turnaround time from image transmission to completion of on-line reading was 50 minutes, but as short as 30 minutes when the conditions for satellite communication were ideal, Dr. Roubidoux said. "The results demonstrate that digital mammograms can be transmitted rapidly by satellite without loss of image quality and can be interpreted remotely," she said.

Because of the rapid turnaround from image acquisition to mammography interpretation, patients in need of follow-up were able to obtain additional breast imaging scans while the mobile mammography unit was still in the area: 58 women were called back for further imaging studies, and 42 of them (72%) had repeat scans performed in the mobile unit on the same day or within 1 to 2 days.

"This project demonstrates efforts by the Sioux tribes and the Indian Health Service to overcome obstacles to screening in remote areas and provide better health care to these women," Dr. Roubidoux said.

The study included 515 mammography examinations performed on 506 women. The mobile mammography unit in the study was equipped with a GE Senograph 2000D digital mammography system, which transmitted screening mammograms via satellite to a GE SenoAdvantage 2.0 workstation, where they were immediately interpreted and reported by radiologists. Turnaround time for reporting included the time required for the transmission of images, receipt of a fax containing a clinical history, interpretation of the screening study by a radiologist, preparation of a paper report, and transmission of the report back to the mobile unit by fax.

Related Videos
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
An expert from Dana-Farber Cancer Institute highlights the unmet needs that sacituzumab govitecan meets in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
An expert from Dana-Farber Cancer Institute highlights data that supported the FDA’s approval of sacituzumab govitecan for advanced hormone receptor–positive, HER2-negative breast cancer.
Related Content